Global Checkpoint Inhibitors Market - By Drug Class: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors, Others (LAG-3, TIGIT, emerging targets); By Application:Lung Cancer, Melanoma, Renal Cell Carcinoma, Bladder Cancer, Head and Neck Cancer, Others (Triple-Negative Breast Cancer, Gastrointestinal Cancers); By End User: Hospitals, Oncology Centers, Research Institutes, Specialty Clinics; By Region: North America, Europe, Asia-Pacific, Latin America, Middle East & Africa.
1 | Market Overview
The global checkpoint inhibitors market is experiencing rapid growth, fueled by the increasing prevalence of cancer and rising demand for immunotherapy treatments. Checkpoint inhibitors work by blocking immune checkpoints such as PD-1, PD-L1, and CTLA-4, thus enabling the immune system to attack cancer cells more effectively.
The expansion of the checkpoint inhibitors market is driven by rising approvals of new indications, growing oncology research, and ongoing investment in combination therapies. Advances in biomarker-driven patient selection and precision medicine are additionally accelerating the market's growth.
2 | Market Size and Forecast
|
Year |
Market Value (USD Billion) |
Notes |
|
2019 |
23.5 |
Historical benchmark |
|
2024 |
41.9 |
Five-year CAGR 12.1% |
|
2031 |
98.6 |
Seven-year CAGR 12.9% |
The market is projected to more than double by 2031, propelled by wider cancer indication approvals and increased adoption of immunotherapies globally.
3 | Key Market Drivers
4 | Market Challenges
5 | Competitive Landscape
The checkpoint inhibitors market is highly consolidated, dominated by leading pharmaceutical companies with blockbuster oncology drugs.
Market Share Estimates (2024):
|
Company |
Estimated Market Share |
Key Products |
|
Bristol-Myers Squibb |
24% |
Opdivo® (nivolumab), Yervoy® (ipilimumab) |
|
Merck & Co. |
21% |
Keytruda® (pembrolizumab) |
|
Roche (Genentech) |
16% |
Tecentriq® (atezolizumab) |
|
AstraZeneca |
12% |
Imfinzi® (durvalumab) |
|
Others (Pfizer, Novartis, Gilead, BeiGene) |
27% |
Novel and regional checkpoint inhibitors |
6 | Market Segmentation
By Drug Class:
By Application:
By End User:
By Region:
7 | Strategic Outlook
The checkpoint inhibitors market will continue evolving with next-generation checkpoint targets (e.g., LAG-3, TIM-3, TIGIT), biomarker-driven treatments, AI-powered drug discovery, and expansion into early-stage cancers and adjuvant therapy settings.
Need help?
Chat with our team in a minute.